• English
  • 日本語
English
Amractionfund
  • About Us
    • Mission
    • Strategy
    • Who we are
    • Investors
    • Testimonials
  • AMR Innovation Challenge
    • The threat of AMR
    • The pipeline problem
    • A sustainable pipeline
    • The role of the fund
  • Our Investments
    • How it works
    • Scope of our investments
    • Stewardship and Access Principles
    • Our Portfolio
  • Resources
  • Contact Us

      Resources

      Filter by category:
      • All
      • Applications
      • Fund Resources
      • In the News
      • News
      • Newsletters
      • Press Releases
      4 Apr, 2022

      AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals

      AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals   Deals mark an important...

      Read More
      25 Nov, 2021

      We must fix the business model for new antibiotics

      AMR Action Fund CEO Henry Skinner and BIO CEO Dr. Michelle McMurry-Heath co-authored a Fortune op-ed on policy solutions to the...

      18 Nov, 2021

      Pressure grows for market reforms to help tackle ‘silent pandemic’ of AMR

      The Financial Times reported on the challenges of bringing new antibiotics to market and the growing political will to remedy the...

      10 Nov, 2021

      More Investment Sorely Needed to Combat Antimicrobial Resistance

      MedPage today reported on the struggles that some biotechs face as they develop antibiotics. The article featured news from the...

      12 Oct, 2021

      Antibiotic resistance in the patient with cancer

      The current focus on the coronavirus disease 2019 (COVID-19) pandemic means a lack of attention to other health challenges, such as antimicrobial resis- tance.

      12 Oct, 2021

      Legislation Aims to Jump Start Antibiotic Development

      Before joining the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Duffy served as executive vice president and chief scientific officer at Melinta Therapeutics, a developer of new antibiotics.

      12 Oct, 2021

      Drug-resistant Infections Led to $1.9 Billion in Health Care Costs

      Superbugs that are resistant to existing antibiotics already take an enormous toll on health-care systems around the world.

      11 Oct, 2021

      Governments fall behind in race to stem antimicrobial resistance

      When drugmaker AstraZeneca closed down its research and development centre in Bangalore six years ago, some of the local scientists managed to find new jobs at a nearby biotech start-up. Since then, they have been working to tackle a problem which is causing concern among doctors in India and around the world: increasing resistance to antibiotics undermining treatments.

      4 Dec, 2020

      A research and development fund for new treatments for bacteria...

      The current focus on the coronavirus disease 2019 (COVID-19) pandemic means a lack of attention to other health challenges, such as antimicrobial resis- tance.

      2 Dec, 2020

      It's time to fix the antibiotic market...

      We need to keep developing new antibiotics to make sure we can keep protecting ourselves from ever-evolving bacteria

      Show More
      Amractionfund
      © 2022 AMR Action Fund All rights reserved. |
      • Japan Disclaimer
      • Privacy Policy